Evidence map›Paper›PMID 40796992›Full record

SynthesisInflammopharmacology2025

COVID-19 in comorbid chronic diseased patients, pregnant and lactating women: pathophysiology, available drug treatment, and the most suitable protocol regimen in each group.

Hend M Mohamed, Yara Y Elkholy, Yara M Mokhtar, Mirna A Orady, Heba Sh Elmetwaly, Hend Mo Abdelwahab, Yasmeen S Abdelrady, Mohamed M Elgohary, Mohamed Kh Elmahdy

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hend M MohamedPharmacy Practice Department, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
Yara Y ElkholyLevel 5 Pharmacy Students, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
Yara M MokhtarLevel 5 Pharmacy Students, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
Mirna A OradyLevel 5 Pharmacy Students, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
Heba Sh ElmetwalyLevel 5 Pharmacy Students, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
Hend Mo AbdelwahabLevel 5 Pharmacy Students, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
Yasmeen S AbdelradyLevel 5 Pharmacy Students, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt.
Mohamed M ElgoharyDepartment of Neurologicsurgery, Mayo Clinic, Rochester, MN, 55905, USA.
Mohamed Kh ElmahdyDepartment of Pharmacology, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt. mkhalil@horus.edu.eg.ORCID http://orcid.org/0009-0008-7321-8023

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Comorbidities such as diabetes, chronic cardiovascular diseases, pulmonary diseases, liver diseases, and renal diseases exacerbate the disease, particularly in older patients, pregnant and lactating women.

objectiveWe performed a systematic review to identify all studies reporting on risks associated with these comorbidities to detect the cause of severity of COVID-19 in these diseases and further selection of the most suitable treatment in each disease.

methodsAn extensive literature search was performed in the PubMed, Cochrane, and Web of Science databases gathering all available articles. We only selected case-control studies that met inclusion criteria and that focused on high-risk chronic diseased patients, pregnant and lactating women that being infected with COVID-19. Selected studies were grouped into 8 broad categories for review and analysis: (1) pathophysiology of COVID-19, (2) characteristics of COVID-19, (3) common laboratory markers of COVID-19, (4) commonly approved and used treatment of COVID-19, and (5) recommended protocol regimen adjustment in comorbid diseases, pregnant and lactating women.

conclusionThis review focused on pathophysiology of COVID-19 especially in comorbid chronic diseased patients, pregnant and lactating women with the most suitable protocol regimen adjustment in each group.

Indexed as

COVID-19COVID-19 Drug TreatmentLactationPregnancy Complications, InfectiousAntiviral AgentsChronic DiseaseComorbidityFemaleHumansPregnancySARS-CoV-2Antiviral AgentsComorbid diseasesCoronavirusLactationPregnant womenProtocol adjustment

Identifiers

PMID40796992

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.